Abstract
Background
Type 2 diabetes mellitus (T2DM) and class I obesity, which are pandemics of considerable socioeconomic importance, require new treatment modalities due to inadequate control through normal clinical conduct. The aim of the present study was to assess the efficacy and safety of Roux-en-Y gastric bypass (RYGB) in the control of T2DM in patients with a body mass index (BMI) of 30 to 35 kg/m2.
Methods
An observational, retrospective study was carried out at the Universidade Federal de Pernambuco—Brazil. Between 2002 and 2008, 27 patients were submitted to RYGB for the treatment of uncontrolled T2DM, with a mean follow-up period of 20 months. An assessment was performed of the complete resolution of T2DM [HbA1c < 6%/fasting plasma glucose (FPG) < 100 mg/dL/no diabetes medication] and glycemic control. The ethics committee of the university approved the study.
Results
RYGB led to the following results: (1) 23% weight reduction (p < 0.001), BMI stabilized at 25.6 kg/m2 in a mean of 12 months; (2) 46% reduction in glycemia and 27% reduction in HbA1c (p < 0.001); (3) 100% improvement in glycemia and 48% resolution of T2DM; (4) glycemic control was 74% without medication and 93% with medication and five patients required medication in addition to RYGB; (5) mean current FPG is 93 mg/dL and HbA1c is 6%; and (6) there were no severe complications or deaths.
Conclusions
RYGB is a safe and effective option in the treatment of uncompensated T2DM associated to class I obesity.
Similar content being viewed by others
References
National Center for Health Statistics NHANES IV Report. http://www.cdc.gov/nchs/product/pubs/pubd/hestats/obes/obese99.htm2002. Accessed 9 Mar 2009.
AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. AACE diabetes mellitus guidelines. Endocr Pract. 2007;13 Suppl 1:1–68.
World Health Organization. Prevalence of diabetes in the WHO region of the Americas. Disponível em: http://www.who.int/diabetes/facts/world_figures/em/index3.html. Accessed 7 Fev 2009.
American Diabetes Association. Standards of medical care en diabetes (position statements). Diab Care. 2009;32 Suppl 1:S13–61.
Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.
Parnes BL, Main DS, Dickinson LM, et al. Clinical decisions regarding HbA1c results in primary care: a report from CaReNet and HPRN. Diab Care. 2004;27(1):13–6.
Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diab Care. 2004;27(1):17–20.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery, a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. JAMA. 2009;122:248–56.
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741–9.
Cummings DE, Overduin J, Foster-Schubert KE, et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109–15.
Cummings DE, Overduin J, Foster-schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89(6):2608–15.
DePaula AL, Macedo ALV, Rassi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc. 2008;22(3):706–16.
Ramos AC, Galvão Neto MP, Souza YM, et al. Laparoscopic duodenal–jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m2 (LBMI). Obes Surg. 2009;19(3):307–12.
Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Arch Intern Med. 2004;164(12):1395–404.
Cohen R, Pinheiro JS, Correa JL, et al. Laparoscopic Roux-en-Y gastric bypass for BMI 35 kg/m2: a tailored approach. Surg Obes. 2006;2:401–4.
Lee WJ, Wang W, Lee YC, et al. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BM1 > 35 and BM1 < 35 kg/m2. J Gastrointest Surg. 2008;12:945–52.
O’Brien PE, Dixon JB, Playfair J, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program. Med Inter. 2006;144:625–33.
Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA. 2008;299(3):316–23.
Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Sa, V.C.T., Ferraz, A.A., Campos, J.M. et al. Gastric Bypass in the Treatment of Type 2 Diabetes in Patients with a BMI of 30 to 35 kg/m2 . OBES SURG 21, 283–287 (2011). https://doi.org/10.1007/s11695-010-0318-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-010-0318-5